Takeda

Shire dodges pricing questions as lanadelumab’s big day nears
Shire dodges pricing questions as lanadelumab’s big day nears
EP Vantage
Takeda
HAE
lanadelumab
FDA
Flag link:
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
CP Wire
Ambys Medicines
Takeda
Third Rock
Flag link:
Takeda announces new series of non-core-asset sales
Takeda announces new series of non-core-asset sales
GoinPharma
Takeda
Shire
M&A
Flag link:
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Endpoints
Takeda
Shire
M&A
Flag link:
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
RAPS.org
Novartis
Merck
GSK
Gilead Sciences
Bayer
AstraZeneca
AbbVie
Takeda
FDA
DDIs
drug-drug interactions
proton pump inhibitors
Flag link:
More Positive Results For Takeda's Alunbrig Acquisition
More Positive Results For Takeda's Alunbrig Acquisition
CP Wire
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Flag link:
More Positive Results For Takeda's Alunbrig Acquisition
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Flag link:
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
CP Wire
Takeda
vedolizumab
ulcerative colitis
Entyvio
Flag link:
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda
Entyvio
ulcerative colitis
Chron's Disease
Flag link:
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
CP Wire
Takeda
Ovid Therapeutics
TAK-935/OV935
Flag link:
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda
Ovid Therapeutics
developmental epileptic encephalopathies
Flag link:
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
BioSpace
Presage Biosciences
Takeda
Celgene
cancer
diagnostics
Flag link:
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
CP Wire
Takeda
Ninlaro
Multiple Myeloma
Flag link:
FTC Clears Takeda's Acquisition of Shire
FTC Clears Takeda's Acquisition of Shire
CP Wire
FTC
M&A
Takeda
Shire
Flag link:
More than $100 Billion Spent on M&A in the First 6 Months of 2018
More than $100 Billion Spent on M&A in the First 6 Months of 2018
BioSpace
M&A
biotech
Celgene
Sanofi
Impact Biomedicines
Bioverativ
GSK
Takeda
Shire
JNJ
Flag link:
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Endpoints
Takeda
Shire
M&A
Japan
Flag link:
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
Reuters
Takeda
Shire
M&A
shareholders
Flag link:
Public Citizen Calls on FDA to Withdraw Takeda Gout Drug
Public Citizen Calls on FDA to Withdraw Takeda Gout Drug
RAPS.org
Takeda
Public Citizen
gout
Uloric
Flag link:
Bitterly opposed old guard at Takeda wages a last-ditch fight to block ‘foreign blood’s’ $62B Shire buyout
Bitterly opposed old guard at Takeda wages a last-ditch fight to block ‘foreign blood’s’ $62B Shire buyout
Endpoints
Takeda
Shire
Christophe Weber
M&A
Flag link:
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
M&A
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Biogen
Takeda
Regeneron
Alexion
Flag link:

Pages